Search clinical trials for: BIA 2-093 900 mg (Part I)

Total 758 results

Bial - Portela C S.A.

Completed

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

Bipolar I Disorder
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Organon and Co

Completed

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

Spondylitis, Ankylosing
Innovation Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
RedHill Biopharma Limited

Suspended

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Covid19

United States, South Africa
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Dr. Reddy's Laboratories Limited
XenoPort, Inc.

Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Psoriasis

United States
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Hoffmann-La Roche

Completed

Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

Chronic Hepatitis C

United States, Puerto Rico
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Altavant Sciences GmbH
Parexel; Altavant Sciences, Inc.

Completed

Multiple-Ascending Dose in Japanese Patients Bridging Study

Healthy

United States
N-Gene Research Laboratories, Inc.
Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaborators

Terminated

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Germany, Hungary
Altavant Sciences GmbH

Completed

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

Pulmonary Arterial Hypertension

United States, Spain, United Kingdom, Czechia, Serbia, Canada, Poland, Italy, Bosnia and Herzegovina, Austria, Germany, Belgium, Bulgaria, France, Latvia, Moldova, Republic of, Ukraine
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Post Herpetic Neuralgia

Germany
Cortendo AB

Completed

Drug Interaction Study of Levoketoconazole and Metformin

Healthy Subjects

United States
Dr. Reddy's Laboratories Limited

Completed

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

Psoriasis

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058

Cardiovascular Diseases

United Kingdom
RFS Pharma, LLC

Withdrawn

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

Human Immunodeficiency Virus Infection
Virginia Commonwealth University
AbbVie

Withdrawn

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Relapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
Rhodes Pharmaceuticals, L.P.
Purdue Pharma, Canada

Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

ADHD

United States, Canada
Zai Lab (Shanghai) Co., Ltd.

Completed

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Hepatocellular Carcinoma (HCC)

China
GangaGen, Inc.

Completed

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

Bacterial Infections | Infectious Disease

Singapore
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
MediBeacon

Completed

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Acute Kidney Injury

United States
Hoffmann-La Roche

Recruiting

Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (Aldebaran)

Angelman Syndrome

Australia, United States, Spain, Italy, France, Germany
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in an ADULT Workplace Environment

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
AbbVie

Completed

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

Healthy Volunteer

United States
CicloMed LLC
Cmed Clinical Services

Completed

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Hamamatsu University

Completed

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Gastritis Associated With Helicobacter Pylori

Japan
Seoul National University Hospital

Completed

A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin

Human Microbiome

Korea, Republic of
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
Egyptian Liver Hospital
Wadi El Nil Hospital

Completed

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis c

Egypt
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
MedPacto, Inc.

Recruiting

Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Kadmon, a Sanofi Company

Active, not recruiting

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Chronic Graft-versus-host-disease

United States
GlaxoSmithKline

Terminated

A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United Kingdom
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal

3

Subscribe